DUBLIN, November 05, 2021--(BUSINESS WIRE)--The "Airway Management Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Amid the COVID-19 crisis, the global market for Airway Management Devices estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$2.2 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027.
Resuscitators, one of the segments analyzed in the report, is projected to grow at a 6.5% CAGR to reach US$745.1 Million by the end of the analysis period.
The U.S. Accounts for Over 27.1% of Global Market Size in 2020, While China is Forecast to Grow at a 9.7% CAGR for the Period of 2020-2027
The Airway Management Devices market in the U.S. is estimated at US$387.3 Million in the year 2020. The country currently accounts for a 27.06% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$474.3 Million in the year 2027 trailing a CAGR of 9.7% through 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR while Rest of European market (as defined in the study) will reach US$474.3 Million by the year 2027.
Supraglottic Devices Segment Corners a 22.9% Share in 2020
In the global Supraglottic Devices segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$247.5 Million in the year 2020 will reach a projected size of US$377 Million by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$299.6 Million by the year 2027, while Latin America will expand at a 8% CAGR through the analysis period.
KARL STORZ GmbH & Co. KG
An Introduction to Airway Management Devices
A Glance at Major Developments in Airway Management
Airway Management Devices: Current Market Scenario and Outlook
Infraglottic Devices, Comprising Endotracheal Tubes& Tracheostomy Tubes, Remains the Largest Product Category
Supraglottic Airway Devices Emerge as Fastest Growing Segment
Rising Demand for Laryngeal Mask Airways Drives Overall Growth
Noticeable Shift towards Disposables in LMA Procedures
Video Laryngoscopes Come to the Fore to Accelerate Overall Momentum
Offering Inexpensive Option, Video Laryngoscopy Cannibalizes Share of Direct Laryngoscopy
Select Video Laryngoscopes by Year of Launch
While Developed Regions Remain Major Revenue Contributors, Developing Regions Continue to Offer Robust Growth Opportunities
Anaesthesia Laryngeal Masks Airways Market
Impact of Covid-19 and a Looming Global Recession
Increasing Incidence of COPD to Drive Growth
Rise in Surgical Procedures Calls for Airway Management
Increasing Healthcare Expenditure to Foster Growth
Critical Importance of Anesthesia in Operative Procedures Accelerates Market Adoption
Anesthesia Disposable Products: A Review
Role of FDA for Anesthesia Safety
Relevancy of Tracheal Intubation in Ventilation & Oxygenation in Treatment Processes Favors Wider Adoption
High Incidence of Preterm Births to Propel the Demand for Airway Management Devices
Countries with High Rate of Preterm Births Worldwide
Total Preterm Births (in Percentage) in the US: 2010-2018E
Increased Focus on Pediatric Airway Management Drives Market Growth
Hospitals Remain Major End-Use Vertical
Technology Innovations Unfold New Opportunities
Video Technology Peps Up Airway Management
New Generation of Fiberoptic Devices Emerge
Novel Tracheostomy Tube Design Enhances Patient Safety
Technology Improvements Focus on Less Invasive Techniques
Robotics: The New Tech Upgrade
Broad Range of Devices Create the Compulsion for Proper Education & Practical Knowledge
Sustained Image of Flexible Fiberoptic Endoscopy
For more information about this report visit https://www.researchandmarkets.com/r/wkpq4
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005423/en/
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
What happened Shares of Novavax (NASDAQ: NVAX) were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline? Other vaccine stocks aren't falling nearly as much.
Semiconductor giant Advanced Micro Devices (NASDAQ: AMD) stock is up a solid 5.7% as of 2:05 p.m. ET Monday -- the first trading day after the Christmas break. All year long, companies that build things that need semiconductors to run them -- which, at this point in history, means everything from PCs to cellphones to cars to kids' toys -- have struggled to get enough semiconductors to manufacture all the products that their customers want to buy. On the one hand, constrained chip supplies mean semiconductor makers can charge more money for their chips -- but only if they have enough manufacturing capacity to make those chips in the first place.
After revealing a new sedan last week, rumors are swirling around the EV maker's next big announcement.
Apple (NASDAQ: AAPL) shareholders beat the market on Monday as the stock rose 2% by 3:30 p.m. ET compared with a 1% rise in the S&P 500. Apple stock participated in a rally for tech giants that included well-known growth names like Meta Platforms, Nvidia, and Tesla, which all beat the market on Monday. The tech-heavy Nasdaq index was up 1.2% by late Monday compared with a 1.1% boost in the S&P 500.
The Santa Claus rally is off to the best start in over 20 years and historically that bodes well for the entire seasonal period, Dow Jones data show.
BridgeBio Pharma said Monday its Pfizer-rivaling heart disease drug failed in a late-stage test — and BBIO stock crashed to a record low.
Apparently, the woman was listed on a bank account and his bitcoin account — totalling over $50,000 at the time of his death. Typically, joint bank accounts are able to avoid probate. Thus, the financial institutions should be notified of your husband’s passing, and of your existence.
On Dec. 16, high-end electric pickup and SUV maker Rivian Automotive (NASDAQ: RIVN) reported its first-ever quarterly results since going public through its recent IPO. The company delivered 11 electric vehicles (EVs) in total during the third quarter of 2021, bringing in approximately $1 million in revenue. Meanwhile, its market capitalization (market cap) was a princely $100 billion at the time of the quarterly release.
If you have $100 at the ready not needed for bills or emergencies and a brokerage that allows fractional share purchases, you have enough to buy into the following pair of no-brainer stocks right now. Palantir Technologies (NYSE: PLTR) is the Liam Neeson of data analytics stocks: It has a very particular set of skills that were acquired over a very long career. The U.S. military is also a prime customer, using Palantir's technology to coordinate millions of troops around the world.
In the last batch, taxpayers got close to $1,200 back, on average.
S3 Partners Managing Director Ihor Dusaniwsky joins Yahoo Finance Live to review the 2021 performances of notable meme and short seller stocks.
Yahoo Finance crypto reporter David Hollerith explains the rise in the fifth-largest cryptocurrency and why Solana could be poised to gain even more in 2022.
In the meantime, many are generating gushers of cash flow, which they're using to pay big-time dividends. Two lucrative income streams that aren't likely to go away anytime soon are those paid by Kinder Morgan (NYSE: KMI) and Williams Companies (NYSE: WMB). Natural gas pipeline giant Kinder Morgan currently offers a dividend yield of 7%.
Advanced Micro Devices opened higher on Monday and almost immediately gave us the rotation we were looking for. Now, I know new all-time highs by year-end sounds like a stretch — and it won't be easy — but all we need from here is a 7% rally.
Nvidia GPUs power self-driving cars and cloud gaming, with the chip giant also expanding fast into the metaverse. Is Nvidia stock a buy?
Shares of uranium mining company Uranium Energy (NYSEMKT: UEC) snapped a two-day, pre-holiday losing streak -- and snapped back dramatically higher on Monday. Why are Uranium Energy shares glowing green today? As I hinted earlier this month, there's a curious dynamic going on with the uranium prices that underlies the prices of shares of uranium stocks.
Shares of Nvidia (NASDAQ: NVDA) popped on the first trading day after Christmas, up 4.1% as of 12:35 p.m. ET today. There's not a whole lot of news to explain today's pop, but Nvidia stock is most likely moving in response to an optimistic article forecasting tech attractions in 2022. In an article this morning on TrustedReviews.com, the author predicts that Nvidia will launch its next generation of graphics chips, beginning with the Nvidia RTX 4080, sometime toward the end of 2022, and that it will be "the most powerful GPU in the range," and better than anything in the 30-Series line.
When you leave a job, and an IRA rollover is only one way to preserve the money’s tax-deferred status, and it's not always the best.
On Friday, Chinese regulators released a draft of new policies for companies wishing to offer shares in foreign countries. It's not providing much of a boost.
The company, which is sparing its executives from the cut, says it brings benefits in line with what other firms offer. One retiree: ‘If there isn’t a legal obligation, there certainly is a moral obligation.’